GATTO, MARIELE
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 7.542
AS - Asia 3.586
EU - Europa 3.045
AF - Africa 850
SA - Sud America 693
OC - Oceania 93
Continente sconosciuto - Info sul continente non disponibili 43
Totale 15.852
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 7.031
SG - Singapore 1.416
IT - Italia 930
CN - Cina 660
BR - Brasile 445
NL - Olanda 443
HK - Hong Kong 349
DE - Germania 307
VN - Vietnam 230
FI - Finlandia 158
GB - Regno Unito 122
PL - Polonia 104
SE - Svezia 104
FR - Francia 89
RU - Federazione Russa 83
IN - India 76
IE - Irlanda 65
MX - Messico 49
TR - Turchia 47
AT - Austria 46
KR - Corea 44
AR - Argentina 43
EG - Egitto 43
JP - Giappone 42
CA - Canada 41
ID - Indonesia 41
AO - Angola 38
IQ - Iraq 37
EC - Ecuador 36
KE - Kenya 36
ZA - Sudafrica 35
JO - Giordania 34
GH - Ghana 33
UA - Ucraina 33
ES - Italia 32
GT - Guatemala 31
IR - Iran 31
DO - Repubblica Dominicana 30
NI - Nicaragua 30
SA - Arabia Saudita 30
PE - Perù 29
BG - Bulgaria 28
DZ - Algeria 28
HU - Ungheria 28
KZ - Kazakistan 28
PA - Panama 28
AL - Albania 27
GR - Grecia 27
HN - Honduras 27
AZ - Azerbaigian 26
CI - Costa d'Avorio 26
IL - Israele 26
MK - Macedonia 26
PR - Porto Rico 26
TT - Trinidad e Tobago 26
BY - Bielorussia 25
ET - Etiopia 25
GN - Guinea 25
NC - Nuova Caledonia 25
PY - Paraguay 25
TH - Thailandia 25
TJ - Tagikistan 25
ZW - Zimbabwe 25
AE - Emirati Arabi Uniti 24
CY - Cipro 24
ME - Montenegro 24
NE - Niger 24
BB - Barbados 23
CM - Camerun 23
CV - Capo Verde 23
CZ - Repubblica Ceca 23
IS - Islanda 23
KH - Cambogia 23
LV - Lettonia 23
RS - Serbia 23
SN - Senegal 23
SO - Somalia 23
TL - Timor Orientale 23
BD - Bangladesh 22
CG - Congo 22
CO - Colombia 22
LC - Santa Lucia 22
PH - Filippine 22
PK - Pakistan 22
PS - Palestinian Territory 22
SK - Slovacchia (Repubblica Slovacca) 22
XK - ???statistics.table.value.countryCode.XK??? 22
YE - Yemen 22
BJ - Benin 21
DK - Danimarca 21
JM - Giamaica 21
KG - Kirghizistan 21
NP - Nepal 21
RO - Romania 21
UZ - Uzbekistan 21
VE - Venezuela 21
YT - Mayotte 21
AM - Armenia 20
BE - Belgio 20
CR - Costa Rica 20
Totale 14.898
Salva come PNG Salva come JPEG
Città #
Fairfield 1.102
Ashburn 881
Singapore 780
Woodbridge 556
Chandler 548
Houston 446
Seattle 378
Ann Arbor 372
Cambridge 341
Hong Kong 337
Wilmington 291
Beijing 213
Santa Clara 148
Boardman 136
Los Angeles 122
Padova 115
Munich 112
San Diego 103
Ho Chi Minh City 86
Medford 82
Princeton 80
New York 76
Des Moines 73
Helsinki 73
Chicago 66
Bytom 65
Dublin 60
Hefei 51
Nanjing 43
Hanoi 42
São Paulo 41
Buffalo 40
Milan 39
Salt Lake City 39
Amman 33
Luanda 33
Turku 32
Nairobi 30
Redondo Beach 30
Managua 29
Rome 28
Dong Ket 26
London 26
Warsaw 26
Conakry 25
Nuremberg 25
Vienna 25
Abidjan 24
Baku 24
Harare 24
Noumea 24
Seoul 24
Dakar 23
Dushanbe 23
Lima 23
Panama City 23
Phnom Penh 23
Accra 22
Tokyo 22
Athens 21
Castries 21
Dili 21
Podgorica 21
Praia 21
Addis Ababa 20
Bishkek 20
Bridgetown 20
Cairo 20
Cotonou 20
Falkenstein 20
Guatemala City 20
Kampala 20
Dallas 19
Dearborn 19
Minsk 19
Niamey 19
Stockholm 19
Djibouti 18
Falls Church 18
Montevideo 18
Naples 18
Papeete 18
Pristina 18
Riga 18
Tampa 18
Tashkent 18
Bologna 17
Brooklyn 17
Havana 17
Kingstown 17
Nassau 17
San José 17
Ulan Bator 17
Yerevan 17
Libreville 16
Amsterdam 15
Johannesburg 15
Limassol 15
Montreal 15
Reykjavik 15
Totale 9.333
Salva come PNG Salva come JPEG
Nome #
ISEV2022 Abstract Book 886
MicroRNAs in idiopathic inflammatory myopathies: state-of-the-art and future perspectives 295
Effects of Belimumab on Flare Rate and Expected Damage Progression in Patients With Active Systemic Lupus Erythematosus. 254
Clinical predictors of response and discontinuation of belimumab in patients with systemic lupus erythematosus in real life setting. Results of a large, multicentric, nationwide study 248
Anti-dsDNA antibody isotypes in systemic lupus erythematosus: IgA in addition to IgG anti-dsDNA help to identify glomerulonephritis and active disease. 224
Advances in the Diagnosis and Classification of Systemic Lupus Erythematosus 216
Transcriptional network profile on synovial fluid T cells in psoriatic arthritis 215
PTX3, Anti-PTX3, and Anti-C1q Autoantibodies in Lupus Glomerulonephritis. 208
Early disease and low baseline damage predict response to belimumab in patients with systemic lupus erythematosus 207
Lupus low disease activity state is associated with a decrease in damage progression in Caucasian patients with SLE, but overlaps with remission 205
SARS-CoV-2 infection in patients with autoimmune rheumatic diseases in northeast Italy: A cross-sectional study on 916 patients 201
17-β-estradiol affects BLyS serum levels and the nephritogenic autoantibody network accelerating glomerulonephritis in NZB/WF1 mice. 197
Diagnostic and prognostic role of renal histopathology in rheumatic diseases 195
A case of progressive multifocal leukoencephalopathy in a lupus patient treated with belimumab--comments on article by Fredericks et al. 193
Overlap connective tissue disease syndromes. 191
Changing patterns in clinical-histological presentation and renal outcome over the last five decades in a cohort of 499 patients with lupus nephritis 188
SERPINB3 delays glomerulonephritis and attenuates the lupus-like disease in lupus murine models by inducing a more tolerogenic immune phenotype 188
The effect of different durations of remission on damage accrual: results from a prospective monocentric cohort of Caucasian patients 187
Clinical Guidelines and Definitions of Autoinflammatory Diseases: Contrasts and Comparisons with Autoimmunity-a Comprehensive Review. 183
The clinical features, diagnosis and classification of dermatomyositis. 183
Effectiveness, Tolerability, and Safety of Belimumab in Patients with Refractory SLE: a Review of Observational Clinical-Practice-Based Studies 182
Anti-MDA5 dermatomyositis: an update from bench to bedside 181
Cardiovascular risk factors, burden of disease and preventive strategies in patients with systemic lupus erythematosus: A literature review 177
Immunization with pentraxin 3 (PTX3) leads to anti-PTX3 antibody production and delayed lupus-like nephritis in NZB/NZW F1 mice. 177
The olfactory function is impaired in patients with idiopathic inflammatory myopathies. 173
Success and failure of biological treatment in systemic lupus erythematosus: A critical analysis 173
Lupus nephritis: clinical presentations and outcomes in the 21st century 172
Premature coronary heart disease in SLE: can we prevent progression? 170
IL-12 and IL-23/Th17 axis in systemic lupus erythematosus 170
Remission in systemic lupus erythematosus: Testing different definitions in a large multicentre cohort 169
Belimumab: a step forward in the treatment of systemic lupus erythematosus 168
Prolonged remission in Caucasian patients with SLE: prevalence and outcomes 166
Rheumatic and autoimmune thyroid disorders: a causal or casual relationship? 163
Lack of EULAR/ERA-EDTA response at 1 year predicts poor long-term renal outcome in patients with lupus nephritis 163
Emerging and critical issues in the pathogenesis of lupus. 162
Correction to: Effectiveness, Tolerability, and Safety of Belimumab in Patients with Refractory SLE: a Review of Observational Clinical-Practice-Based Studies. 162
New therapeutic strategies in systemic lupus erythematosus management 162
Predictors of maternal and fetal complications in SLE patients: a prospective study. 159
Interstitial lung disease with and without progressive fibrosing phenotype in patients with idiopathic inflammatory myopathies: data from a large multicentric cohort 158
Clinical and pathologic considerations of the qualitative and quantitative aspects of lupus nephritogenic autoantibodies: A comprehensive review 157
Physician’s global assessment is often useful in SLE, but not always: the case of clinical remission 155
Rituximab in refractory idiopathic inflammatory myopathies and antisynthetase syndrome: personal experience and review of the literature. 154
Durable renal response and safety with add-on belimumab in patients with lupus nephritis in real-life setting (BeRLiSS-LN). Results from a large, nationwide, multicentric cohort 153
Novel Pathogenic Pathways and Therapeutic Implications in Lupus Nephritis: The Emerging Role of PTX3-Related Immunity 151
Prevalence, outcome and management of patients with SLE and secondary antiphospholipid antibody syndrome after aPL seroconversion 150
Nephritogenic-antinephritogenic antibody network in lupus glomerulonephritis 147
The interferon in idiopathic inflammatory myopathies: Different signatures and new therapeutic perspectives. A literature review 146
Immunization with Pentraxin3 prevents transition from subclinical to clinical lupus nephritis in lupus-prone mice: insights from renal ultrastructural findings.   144
Immunosuppressive therapy withdrawal after remission achievement in patients with lupus nephritis 142
Assessment of disease activity and damage in SLE: Are we there yet? 142
Circulating Pentraxin3-Specific B Cells Are Decreased in Lupus Nephritis 141
Multicentric study comparing cyclosporine, mycophenolate mofetil and azathioprine in the maintenance therapy of lupus nephritis: 8 years follow up 141
Prevalence and predictors of flare after immunosuppressant discontinuation in patients with systemic lupus erythematosus in remission 140
Optimizing outcome in SLE: treating-to-target and definition of treatment goals. 139
Cytoarchitectureal changes in hippocampal subregions of the NZB/W F1 mouse model of lupus 138
Autoantibody testing in patients with myositis: clinical accuracy of a multi parametric line immunoassay 135
The body against self: autoinflammation and autoimmunity. 132
Thoracic Involvement in Systemic Autoimmune Rheumatic Diseases: Pathogenesis and Management 132
Circulating extracellular vesicles and small non-coding RNAs cargo in idiopathic inflammatory myopathies reveal differences across myositis subsets 131
Human papillomavirus vaccine and systemic lupus erythematosus. 130
Maternal outcome in pregnant women with lupus nephritis. A prospective multicenter study 130
Vaccination of mice for research purpose: alum is as effective as and safer than complete Freund adjuvant. 129
Preclinical and early systemic lupus erythematosus 128
Rituximab-associated hypogammaglobulinaemia in ANCA-associated vasculitis and connective tissue diseases: a longitudinal observational study 124
Serpins, Immunity and Autoimmunity: Old Molecules, New Functions. 123
Unresolved and critical issues in autoimmune rheumatic diseases 123
Controversies in Rheumatology and Autoimmunity: Approaching the truth by the discussion 122
IgG anti-Pentraxin 3 antibodies are a novel biomarker of ANCA-associated vasculitis and better identify patients with eosinophilic granulomatosis with polyangiitis 122
Pulmonary involvement in antisynthetase syndrome 121
International consensus: What else can we do to improve diagnosis and therapeutic strategies in patients affected by autoimmune rheumatic diseases (rheumatoid arthritis, spondyloarthritides, systemic sclerosis, systemic lupus erythematosus, antiphospholipid syndrome and Sjogren's syndrome)?: The unmet needs and the clinical grey zone in autoimmune disease management 120
Current clinical and therapeutic approach to tumour-like mass lesions in granulomatosis with polyangiitis 120
Galectin-3 in autoimmunity and autoimmune diseases 119
Role of galectin-3 in autoimmune and non-autoimmune nephropathies 119
How I treat idiopathic patients with inflammatory myopathies in the clinical practice 119
Nonimmune mechanisms in idiopathic inflammatory myopathies 117
Lymphocyte immunophenotyping in inflammatory myositis: a review 117
Autophagy in human health and disease. 116
Diagnosis and management of lung involvement in systemic lupus erythematosus and Sjögren’s syndrome: a literature review 116
The SLE-DAS provides an accurate and feasible flare tool in the clinical setting: a validation study 116
Size-Exclusion Chromatography Combined with Ultrafiltration Efficiently Isolates Extracellular Vesicles from Human Blood Samples in Health and Disease 115
New onset and flare of rheumatic diseases following COVID-19 vaccination are mild and respond well to treatment: 9-month follow-up data from a single centre cohort 115
Value and goals of treat-to-target in systemic lupus erythematosus: knowledge and foresight. 115
What are the topics you care about making trials in lupus more effective? Results of an Open Space meeting of international lupus experts 113
Fetal outcome and recommendations of pregnancies in lupus nephritis in the 21st century. A prospective multicenter study 110
Caveats and pitfalls in defining low disease activity in systemic lupus erythematosus 107
Clinical and histological findings at second but not at first kidney biopsy predict end-stage kidney disease in a large multicentric cohort of patients with active lupus nephritis 105
Efficacy and safety of off-label use of rituximab in refractory lupus: data from the Italian Multicentre Registry 105
In-/off-label use of biologic therapy in systemic lupus erythematosus 103
The new targeted therapy in systemic lupus erythematosus: Is the glass half-full or half-empty? 103
CCL18 as a Biomarker of Interstitial Lung Disease (ILD) and Progressive Fibrosing ILD in Patients with Idiopathic Inflammatory Myopathies 101
Frequency and clinical correlates of antiphospholipid antibodies arising in patients with SARS-CoV-2 infection: findings from a multicentre study on 122 cases 100
CHARACTERIZATION OF EXTRACELLULAR VESICLES SURFACE LYMPHOCYTES MARKERS AND MICRORNA CARGO IN PATIENTS AFFECTED WITH IDIOPATHIC INFLAMMATORY MYOPATHIES 100
B Cell Kinetics upon Therapy Commencement for Active Extrarenal Systemic Lupus Erythematosus in Relation to Development of Renal Flares: Results from Three Phase III Clinical Trials of Belimumab 98
Detection of Myositis Autoantibodies by Multi-Analytic Immunoassays in a Large Multicenter Cohort of Patients with Definite Idiopathic Inflammatory Myopathies 97
The Management of Systemic Lupus Erythematosus (SLE) Patients in Remission 97
Defining the targets in SLE management: insights and unmet gaps 93
Early B Cell and Plasma Cell Kinetics Upon Treatment Initiation Portend Flares in Systemic Lupus Erythematosus: A Post-Hoc Analysis of Three Phase III Clinical Trials of Belimumab 91
Can we withdraw immunosuppressants in patients with lupus nephritis in remission? An expert debate 89
Evaluation of extracellular vesicles as potential biomarkers of myositis 87
Three years is the minimal effective duration of sustained clinical remission which prevents impaired kidney function and damage accrual in lupus nephritis 85
Totale 15.501
Salva come PNG Salva come JPEG
Categoria #
all - tutte 50.331
article - articoli 48.893
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 99.224
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021940 0 0 0 0 16 42 49 108 111 224 129 261
2021/20221.267 51 135 135 83 81 116 76 114 63 51 81 281
2022/20231.010 202 117 29 138 129 138 13 76 95 12 39 22
2023/2024763 27 74 88 67 63 104 60 47 44 24 79 86
2024/20253.457 13 185 119 143 320 108 674 450 222 137 455 631
2025/20265.818 599 839 1.499 1.874 1.007 0 0 0 0 0 0 0
Totale 16.028